Clinical trials: Takayasu Arteritis
Takayasu's Arteritis, Giant Cell Arteritis
Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis
Giant cell arteritis (GCA) and Takayasu's arteritis (TAK) are diseases that cause swelling of the arteries in the head, neck, upper body, and arms.
- Trial name
- NCT00556439
- Testing
- Abatacept
- Where
- 10 sites in United States, Canada
- Volunteers
- 97 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Giant Cell Arteritis, Takayasu Arteritis
Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis
Vasculitis occur when the body's immune system, rather than protecting the body, attacks blood vessels, causing injury to the vessel and the part of the body it supplies with blood.
- Conditions
- Giant Cell Arteritis, Takayasu Arteritis, Cogan Syndrome, Relapsing Polychondritis
- Trial name
- BIOVAS (NCT05168475)
- Testing
- Rituximab, Infliximab, Tocilizumab
- Where
- 5 sites in United Kingdom
- Volunteers
- 22 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Takayasu Arteritis
A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)
The purpose of this study is to evaluate the efficacy of ustekinumab compared to placebo, in combination with oral glucocorticoid (GC) taper regimen, in participants with relapsing Takayasu Arteritis (TAK).
- Trial name
- NCT04882072
- Testing
- Ustekinumab, Glucorticoid Taper Regimen
- Where
- 27 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Janssen Pharmaceutical K.K.